Biotech Firm Blondin To Collaborate On Breast Cancer Research Project In Finland

By Dawn Azok
Made in Alabama

A key executive for Blondin Bioscience LLC is a collaborator on a prestigious grant awarded by the Academy of Finland that will aid in the study of breast cancer therapies.

Dr. Katri Selander, founder and chief scientific officer of the Birmingham-based biotech startup, is a collaborator on the three-year, $474,000 grant awarded to Dr. Johanna Tuomela, who is with the University of Turku, one of the largest universities in Finland.

Tuomela studies the role of inflammasomes, a component of the innate immune system, and a protein called TLR9 in bisphosphonate responses in bone tissue and breast cancer. The grant may help identify patients who benefit most from bisphosphonates, a class of drugs that was initially used for osteoporosis but is now also used as adjuvant treatment in breast cancer.“Companies like Blondin are at the heart of Alabama’s emerging bioscience sector, and it’s exciting to see collaborations like this one that link our talented researchers with counterparts in Europe,” said Greg Canfield, secretary of the Alabama Department of Commerce.

Please visit Alabama News Center for the Full Article

Tags: ANC

Category: ALL POSTS, Partner News Stories